Ovarian Cancer
Ovarian Adenocarcinoma
Female, 70 years
Patient Internal ID: 1591653811
ICD-10 code
C56 Malignant Neoplasm of Ovary
Diagnosis (Incl. Metastases/Stage) and Year
September 2017
Recurrent Ovarian Adenocarcinoma, High Grade, Platinum Resistant BRCA Wild Type. Disease progression in April 2019, April 2021- Mass in Pelvic area.
Previous Treatment
Chemotherapy (Carboplatin, Paclitaxel, Avastin), Surgery, Chemotherapy (Carboplatin, Paclitaxel, Avastin), Chemotherapy (Carboplatin & Liposomal Doxorubicin), Target Therapy (Niraparib), Chemotherapy (Carboplatin/ Gemcitabine), Chemotherapy (Carboplatin).
Prognosis and Survival Expectation
The prognosis remains poor. The average relative 5-year survival rate for those diagnosed with Distant Spread Ovarian Cancer is about 31%. The median survival of Metastatic Ovarian Cancer is 24.7 months (Swedish Cancer Registry).
Treatment Provided
Allogeneic Umbilical Cord Blood Derived NK Cells (4 doses) with Interleukin-2 over a period of 1 month. Additionally, the patient received Neoantigen Vaccines with Specific Peptides (10 doses).
Patient Survival/Condition and Year
Date of Review: 10/02/2024
The patient has survived for 6,5 years since the diagnosis and 46 months since disease progression. At the time of review, disease progression had been detected. It can be concluded that the addition of Immunotherapy, alongside Surgery, Chemotherapy, and Target Therapy, has extended patient survival by an estimate of around 21 months so far.
